Collage photo of Elisa Agostinetto and Marleen Kok
Jul 26, 2024, 00:03
Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522
Elisa Agostinetto shared on X:
“Out in JCO a must-read by Marleen Kok on the limitations of KEYNOTE-522.
To control (financial) toxicity, agencies must limit trial designs where the relative contribution of each phase of treatment (pre vs. postop) cannot be established.”
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer published in JCO
Autors:
Source: Elisa Agostinetto/X
Elisa Agostinetto is a Clinical Research Fellow at the Institute Jules Bordet in Brussels, Belgium. She is also a Resident in Medical Oncology at Humanitas Research Hospital in Milan, Italy. Agostinetto specializes in Breast Cancer and Immuno-Oncology.
Antonio C. Wolff
Denis Lacombe
Elisa Agostinetto
Elizabeth A. Mittendorf
Erin Reardon
Gabe Sonke
Giuseppe Curigliano
JCO
Jochen K. Lennerz
Justin M. Balko
KEYNOTE-522
Lajos Pusztai
Marleen Kok
Michail ignatiadis
Miguel Martin
Priyanka Sharma
Robbert-Jan Gielen
Roberto Salgado
Sabine Linn
Sara M. Tolaney
Sherene Loi
Sibylle Loibl
Sunil Badve
Suzette Delaloge
Sylvia Adams
Tim Robinson